Rank |
Status |
Study |
1 |
Recruiting
|
Childhood Alopecia Areata Study Using the 308-nm Excimer Laser
Condition: |
Alopecia Areata |
Interventions: |
Device: 308-nm excimer laser to Alopecia patch; Device: Liquid light guide tip on laser |
Outcome Measures: |
The goal of this study is to assess the feasibility, safety and response to treatment of the use of the 308-nm excimer laser in children diagnosed with patch type Alopecia areata involving the scalp, present for more than 6 months duration; Evaluate the feasibility and safety of twice-weekly excimer laser treatments over a period of 12 weeks |
|
2 |
Recruiting
|
Alopecia Areata Registry
Conditions: |
Alopecia Areata; Alopecia Totalis; Alopecia Universalis; Autoimmune Hair Loss; Alopecia Partialis |
Intervention: |
|
Outcome Measure: |
Alopecia Areata Registry |
|
3 |
Recruiting
|
Intralesional Steroids in the Treatment of Alopecia Areata
Condition: |
Alopecia Areata |
Interventions: |
Drug: Triamcinolone 2.5 mg/ml; Drug: Triamcinolone 5 mg/ml; Drug: Triamcinolone 10 mg/ml; Drug: Intralesional Saline |
Outcome Measures: |
SALT Score; Number of adverse events |
|
4 |
Unknown †
|
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
Conditions: |
Alopecia Areata; Alopecia; Balding |
Interventions: |
Procedure: Hair transplantation; Procedure: Hypodermic needle irritation |
Outcome Measure: |
Change in follicular growth |
|
5 |
Not yet recruiting
|
A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
Condition: |
Alopecia Areata |
Interventions: |
Drug: Abatacept; Drug: placebo |
Outcome Measures: |
SALT Score (Severity of Alopecia Tool); Efficacy; Safety |
|
6 |
Recruiting
|
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Condition: |
Alopecia Areata |
Intervention: |
Drug: Abatacept |
Outcome Measures: |
SALT Score (Severity of Alopecia Tool); Efficacy; Safety |
|
7 |
Recruiting
|
Effect of PRP on the Therapy for Hair Growth
Condition: |
Hair Loss/Baldness |
Intervention: |
Other: hair loss, baldness (patient's own platelet-rich plasma) |
Outcome Measure: |
examination the effect of PRP on hair loss/baldness |
|
8 |
Recruiting
|
Scalp Cooling to Prevent Chemo-induced Hair Loss
Conditions: |
Breast Cancer; Alopecia |
Interventions: |
Device: PAXMAN Orbis Scalp Cooler; Other: Control No treatment to prevent hair loss |
Outcome Measures: |
Efficacy; Safety |
|
9 |
Recruiting
|
An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata
Condition: |
Alopecia Areata |
Intervention: |
Drug: Ruxolitinib |
Outcome Measures: |
Change in SALT Score; Change in Percentage of Hair Loss; Change in Patient Global Assessment; Change in Physician Global Assessment (PGA) Score; Patient Quality of Life Assessment Score; Incidence of Adverse Effects |
|
10 |
Recruiting
|
Androgenetic Alopecia in Fabry Disease
Condition: |
Fabry Disease |
Intervention: |
|
Outcome Measures: |
No and frontal only androgenetic Alopecia; Vertex only and frontal and vertex androgenetic Alopecia. |
|
11 |
Recruiting
|
Excimer Light for Alopecia Areata
Condition: |
Alopecia Areata |
Intervention: |
Procedure: UVB excimer light |
Outcome Measures: |
Change in the percentage of hair regrowth for each half. We will consider the treamtment successful if there was ≥50% hair regrowth from baseline.; Change in hair count and caliber in each half; Assessment of side effects in each half |
|
12 |
Unknown †
|
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
Condition: |
Alopecia Areata |
Intervention: |
Drug: Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units |
Outcome Measures: |
To evaluate hair regrowth with Alopecia areata subcutaneous injections of Botulinum toxin A; Hair regrowth will be assessed after 3 months and 6 months |
|
13 |
Unknown †
|
Pharmacogenomic Study of Androgenetic Alopecia
Condition: |
Androgenetic Alopecia |
Intervention: |
|
Outcome Measure: |
|
|
14 |
Not yet recruiting
|
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Condition: |
Alopecia |
Interventions: |
Drug: Dutasteride; Drug: Placebo |
Outcome Measures: |
Proportion of subjects with a change in sexual function defined as a negative change from baseline in the IIEF-EF score of >=4 units or a score of <=25 on or before Week 24; Proportion of subjects with a negative change from baseline in the IIEF-EF score of >=4 units or a score of <=25 on or before Weeks 4 and 12 as well as the Follow-up Visit; Change from baseline in total score of the IIEF at Weeks 4, 12, and 24 as well as the Follow-up Visit; Change from baseline in the individual domain scores: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall sexual satisfaction, of the IIEF at Weeks 4, 12 and 24 as well as the Follow-up Visit; Change from baseline in subject satisfaction with hair growth as assessed by the total score of the Hair Growth Satisfaction Scale (HGSS) at Weeks 12 and 24; Change from baseline in the total score of the Dermatology Life Quality Index (DLQI) at Weeks 12 and 24; Occurrence of adverse events related to sexual dysfunction |
|
15 |
Unknown †
|
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
Condition: |
Alopecia |
Intervention: |
Drug: Clobetasol Propionate 0.05% Emollient Foam |
Outcome Measures: |
Improvement of pruritis, tenderness, and pain; Absence of inflammation on biopsy |
|
16 |
Recruiting
|
The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata
Condition: |
Alopecia Areata |
Interventions: |
Drug: Botulinum toxin type A; Drug: Triamcinolone acetonide |
Outcome Measures: |
The percentage of terminal hair regrowth after intralesional botulinum toxin A injection; Possible side effects of intralesional botulinum toxin a injection |
|
17 |
Recruiting
|
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata
Condition: |
Alopecia Areata |
Intervention: |
Drug: Interleukin-2 |
Outcome Measures: |
Number of patients who obtained an improvement of at least 90% of the score validated severity score in Alopecia areata in 2 months.; Evaluation of the quality of life |
|
18 |
Unknown †
|
Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women
Condition: |
Alopecia |
Intervention: |
Drug: AS101 |
Outcome Measures: |
hair density; Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,; Self-administered satisfaction questionnaire |
|
19 |
Unknown †
|
Vytorin in the Treatment of Alopecia Areata
Condition: |
Alopecia Areata |
Intervention: |
Drug: vytorin |
Outcome Measures: |
20% Hair regrowth; maintenance of hair |
|
20 |
Unknown †
|
Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
Condition: |
Breast Cancer |
Intervention: |
|
Outcome Measures: |
Severity of Alopecia Tool (SALT); Comparison of Tamoxifen, AI or Tamoxifen plus AI |
|